SDZXF (Sandoz Group AG) Ending Cash Position: $1,739 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SDZXF Sandoz Group AG SDZXF
17 GF Score
Price $79.90
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Ending Cash Position?

Sandoz Group AG SDZXF -0.62% 17 Ending Cash Position is $1,739 Mil as of Dec. 2025. GuruFocus rates SDZXF with a GF Score™ of 17/100. The stock has 6 warning signs investors should review.

Sandoz Group AG's Ending Cash Position for the quarter that ended in Dec. 2025 was $1,739 Mil.

Sandoz Group AG's quarterly Ending Cash Position increased from Dec. 2024 ($1,191 Mil) to Jun. 2025 ($1,389 Mil) and increased from Jun. 2025 ($1,389 Mil) to Dec. 2025 ($1,739 Mil).

Sandoz Group AG's annual Ending Cash Position increased from Dec. 2023 ($1,109 Mil) to Dec. 2024 ($1,191 Mil) and increased from Dec. 2024 ($1,191 Mil) to Dec. 2025 ($1,739 Mil).

Sandoz Group AG Ending Cash Position Related Terms

Sandoz Group AG Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Ending Cash Position Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
74.00 1,109.00 1,191.00 1,739.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial 1,109.00 701.00 1,191.00 1,389.00 1,739.00
SDZXF
17GF Score
Sandoz Group AG SDZXF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sandoz Group AG's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1191+548
=1,739

Sandoz Group AG's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1389+350
=1,739

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1,739 Mil mean?
Sandoz Group AG (SDZXF) has a Ending Cash Position of $1,739 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Ending Cash Position too high?
Sandoz Group AG's current Ending Cash Position is $1,739 Mil. Overall, Sandoz Group AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Ending Cash Position compare to ZTS and UTHR?
Sandoz Group AG's Ending Cash Position of $1,739 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Ending Cash Position is $1,739 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current Ending Cash Position of $1,739 Mil. The current Ending Cash Position is $1,739 Mil. Sandoz Group AG's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current Ending Cash Position is $1,739 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
17GF Score

Get the complete analysis for SDZXF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.90
Price